ENDV (Endonovo Therapeutics) Revenue: $0.00 Mil (TTM As of Jun. 2025)


What is Endonovo Therapeutics Revenue?

Endonovo Therapeutics ENDV Revenue is $0.00 Mil as of Jun. 2025. The stock has 3 warning signs investors should review.

Endonovo Therapeutics's revenue for the three months ended in Jun. 2025 was $0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2025 was $0.00 Mil. Endonovo Therapeutics's Revenue per Share for the three months ended in Jun. 2025 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2025 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Endonovo Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 77.40% per year. The lowest was -86.90% per year. And the median was -71.10% per year.

Endonovo Therapeutics  (OTCPK:ENDV) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Endonovo Therapeutics Revenue Related Terms

Endonovo Therapeutics Revenue Historical Data

* Premium members only.

The historical data trend for Endonovo Therapeutics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Endonovo Therapeutics Revenue Chart

Endonovo Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 0.07 0.14 0.14 0.01

Endonovo Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ENDV vs RGBP, SIGY, CNBX: Revenue Comparison

For the Biotechnology subindustry, Endonovo Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Endonovo Therapeutics Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Endonovo Therapeutics's Revenue distribution charts can be found below:

* The bar in red indicates where Endonovo Therapeutics's Revenue falls into.


Endonovo Therapeutics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $0.00 Mil mean?
Endonovo Therapeutics (ENDV) has a Revenue of $0.00 Mil as of Jun. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Endonovo Therapeutics and its competitors.
Is Endonovo Therapeutics' Revenue too high?
Endonovo Therapeutics' current Revenue is $0.00 Mil.
How does Endonovo Therapeutics' Revenue compare to RGBP and SIGY?
Endonovo Therapeutics' Revenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Endonovo Therapeutics and its competitors. Endonovo Therapeutics's current Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Endonovo Therapeutics stock overvalued right now?
Endonovo Therapeutics (ENDV) has a current Revenue of $0.00 Mil. The current Revenue is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Endonovo Therapeutics (ENDV), the current Revenue is $0.00 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Endonovo Therapeutics Business Description

Address 6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367
Endonovo Therapeutics Inc develops, manufactures and distributes revolutionary medical devices that utilize Pulsed Electro Magnetic Field (PEMF) therapy that are focused on the rapid recovery of wounds and reduction of pain, edema and inflammation on and in the human body.